We read, with great interest, the results published by Arshad and colleagues concerning the potential association between treatment with hydroxychloroquine with or without azithromycin and in-hospital mortality in patients with COVID-19 ([@bib0005]). The reported treatment benefit contradicts that reported elsewhere, including a recent study at US Veterans Affairs Hospitals that showed an almost perfectly inverse risk of mortality (HR = 2.61; 95% CI, 1.10--6.10) ([@bib0020]). Although Lee et al. provided an excellent commentary on the potential for immortal time bias and selection bias in this work ([@bib0015]), the following design and analysis flaws further threaten the validity of the reported findings.

First, corticosteroid use was common in patients who received hydroxychloroquine with or without azithromycin, 79%, and 74%, respectively. It is unclear when in the course of care, adjunctive therapy, including steroids and tocilizumab, was initiated. Without disclosing the treatment protocol at each of the six centers, all we can conclude is that steroid use was not consistent at baseline and, therefore, should have been treated as a time-dependent covariate ([@bib0025]). This may indicate that an initial clinical decline in the hydroxychloroquine arms was masked by subsequent corticosteroid initiation.

The authors' efforts to control confounding create additional confusion. Reportedly, 25% of mSOFA scores were missing and "no imputations...\[were\] made for missing data..." Yet the Cox model was adjusted for "clinical disease severity (mSOFA, O~2~ saturation)." Table 2 states that all 2,541 cases were included yet shows no effect for mSOFA score, indicating that either all cases were included or the model was not adjusted for severity, as discussed in the text. Dichotomizing age is also concerning, given the established association between COVID-19 mortality and age. Dichotomizing age robs information from the model and is a significant threat to validity.

Finally, in the propensity scored (PS) model, the authors redefined exposure as hydroxychloroquine, or nothing; the authors did not include azithromycin as a covariate in the PS generating model. With so few matched pairs included in the model (n = 190), the omission of this potential confounder, especially one the Cox model showed to be associated with the outcome, should not be taken lightly. Furthermore, we are left to question why exposure was redefined, given the availability of established methods to compare multiple treatment groups using inverse probability of treatment weighting ([@bib0010]). In light of these significant threats to validity, we urge clinicians who treat patients with COVID-19 to interpret and apply the contradictory findings of this study cautiously.
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